Cerus (CERS) Peer Comparison

$2.66

$-0.07 (-2.39%)

As on 28-Aug-2026 13:37EDT

Market cap

$566 Mln

Revenue (TTM)

$222 Mln

P/E Ratio

--

P/B Ratio

8

Div. Yield

0 %

Edit

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	566	12,753	10,906	10,222	9,762
Revenue ($ Mln)	222	1,505	613	785	2,589
Net Profit ($ Mln)	-6.78	160.59	-188.05	41.54	222.40
Net Margin (%)	-3.06	10.67	-30.68	5.29	8.59
RoE (%)	-10.03	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	8.03	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	221.55	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	106.24	483.98	127.96	384.30	1,245.50
Gross Profit	112.29	942.44	393.22	347.62	1,343.60
Operating Expenses	116.93	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-1.62	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-6.44	203.83	-192.83	52.15	350.40
Provision for Tax	0.39	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-6.78	160.59	-188.05	41.54	222.40
Minority Interest	0.05	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	70.02	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.05	0.00	0.00	0.00	0.00
Non-Current Liabilities	48.68	210.18	135.71	705.49	2,116.80
Current Liabilities	85.79	233.78	102.33	132.66	961.30
Total Liabilities	221.86	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	47.88	630.60	404.74	1,749.63	7,231.50
Current Assets	157.31	1,344.12	515.78	1,200.55	3,020.50
Total Assets	221.86	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	76.80	212.71	102.84	690.94	1,203.70
Net Current Assets	71.52	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	11.36	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-8.13	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	4.96	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-9.91	11.76	-22.53	1.79	8.98
ROE (%)	-10.03	10.86	-28.10	1.97	3.04
ROA (%)	-2.31	7.95	-18.00	1.36	2.02
EBIT Margin (%)	0.55	13.63	-30.58	9.87	-5.99
Net Margin (%)	-3.06	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	15.09	17.55	41.55	16.49	1.37
EBIT Growth (%)	112.23	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	64.07	8.72	-102.66	400.42	-30.32
EPS Growth (%)	65.62	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	20.50	17.33	-12.65	2.16	2.19

Valuation Ratios

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-25.32	68.93	-34.59	189.42	--
Price / Book Value	6.16	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-74.32	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.50	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.48	0.01	0.00	0.01	0.06
Current Ratio	1.83	5.75	5.04	9.05	3.14
Quick Ratio	1.07	3.86	4.46	7.64	2.33
Interest Coverage	0.16	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Cerus (CERS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	13.98	12.65	22.67	20.09	17.06
Asset Turnover	0.75	0.74	0.59	0.26	0.24
Receivable days	53.29	46.54	60.95	72.41	65.39
Inventory Days	183.42	331.92	193.84	146.53	221.09
Payable days	96.72	26.16	60.19	29.05	37.02
Cash Conversion Cycle	139.98	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly